Table 2.

Adverse events occurring in ≥15% of patients with advanced TRK fusion-positive thyroid carcinoma treated with larotrectinib.

Preferred term	Treatment-emergent AEs, n (%)				Treatment-related AEs, n (%)
	Grade 1 or 2	Grade 3	Grade 4	Any grade	Grade 3	Grade 4	Any grade
Myalgia	12 (41)	0	0	12 (41)	0	0	8 (28)
Fatigue	10 (34)	0	0	10 (34)	0	0	8 (28)
Nausea	10 (34)	0	0	10 (34)	0	0	3 (10)
Constipation	9 (31)	0	0	9 (31)	0	0	5 (17)
Cough	8 (28)	1 (3)	0	9 (31)	–	–	–
Dizziness	8 (28)	1 (3)	0	9 (31)	0	0	8 (28)
Peripheral oedema	9 (31)	0	0	9 (31)	0	0	4 (14)
ALT increased	8 (28)	0	0	8 (28)	0	0	8 (28)
Anaemia	4 (14)	4 (14)	0	8 (28)	1 (3)	0	2 (7)
AST increased	8 (28)	0	0	8 (28)	0	0	8 (28)
Arthralgia	7 (24)	0	0	7 (24)	0	0	3 (10)
Diarrhoea	4 (14)	3 (10)	0	7 (24)	0	0	3 (10)
Dyspnoea	6 (21)	1 (3)	0	7 (24)	0	0	1 (3)
Leukocyte count decreased	6 (21)	1 (3)	0	7 (24)	0	0	6 (21)
Lymphocyte count decreased	3 (10)	3 (10)	1 (3)	7 (24)	1 (3)	0	2 (7)
Vomiting	7 (24)	0	0	7 (24)	0	0	2 (7)
Headache	6 (21)	0	0	6 (21)	0	0	1 (3)
Pyrexia	6 (21)	0	0	6 (21)	0	0	1 (3)
Hypoaesthesia	5 (17)	0	0	5 (17)	0	0	3 (10)
Hypocalcaemia	2 (7)	2 (7)	1 (3)	5 (17)	0	0	1 (3)
Nasal congestion	5 (17)	0	0	5 (17)	0	0	1 (3)
Pain in extremity	5 (17)	0	0	5 (17)	0	0	2 (7)
Rash	5 (17)	0	0	5 (17)	0	0	3 (10)

Dashes indicate AEs that were not reported to be treatment-related in any patients.

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRK, tropomyosin receptor kinase.